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Contrasting effects of diclofenac and ibuprofen on active
imatinib uptake into leukaemic cells
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BACKGROUND: The human organic cation transporter-1 (OCT-1) is the primary active protein for imatinib uptake into target
BCR-ABL-positive cells. Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used by chronic myeloid leukaemia (CML)
patients on imatinib to manage musculoskeletal complaints.
METHODS: Here we investigated the impact of NSAIDs on functional activity of the OCT-1 (OCT-1 activity; OA) in CML cells.
RESULTS: Although ten of twelve NSAIDs tested had no significant impact on OA (P40.05), we observed increased OA (27%
increase in K562; 22% increase in KU812 cells, Po0.05) and reduced IC50imatinib when treated with diclofenac. Co-incubation with
imatinib and diclofenac resulted in a significantly lower viable cell number compared with imatinib alone. In contrast, ibuprofen led to
a significant decrease in OA, an increase in IC50imatinib and thus reduced the cytotoxicity of imatinib. In primary CML samples,
diclofenac significantly increased OA, particularly in patients with low OA (o4 ng per 200 000 cells), and significantly decreased
IC50imatinib. Ibuprofen induced significant decreases in OA in CML samples and healthy donors.
CONCLUSION: On the basis of the expected impact of these two drugs on OA, ibuprofen should be avoided in combination with
imatinib. Further studies are warranted regarding the potential benefit of diclofenac to improve OA in a clinical setting.
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Imatinib mesylate is a rationally-designed inhibitor of BCR-ABL
currently used as first-line treatment for chronic phase chronic
myeloid leukaemia (CP-CML). According to the 7-year update of
IRIS (International Randomized Study of Interferon and STI571),
patients treated with imatinib (STI571) achieved an overall
event-free survival of 81% and transformation-free survival
(to accelerated phase/blast crisis) of 93% (Hughes et al, 2010).
Despite these excellent outcomes, suboptimal response or resis-
tance to imatinib was reported soon after the introduction of
imatinib into clinical practice (Gorre et al, 2001; Shah et al, 2002).
Although the presence of mutations within the kinase domain of
BCR-ABL is widely accepted as the most common reason for
secondary imatinib resistance (Gorre et al, 2001; Hughes et al,
2006), the underlying cause of primary resistance is less well
characterised. The human organic cation transporter-1 (OCT-1)
has been identified as the major transporter responsible for
imatinib uptake in CML cells (Thomas et al, 2004). We have
demonstrated that low functional activity of the OCT-1 protein
(OCT-1 activity; OA) measured at the time of diagnosis, results in
reduced imatinib-mediated in vitro tyrosine kinase inhibition
(White et al, 2005) and is associated with a poor outcome in
CP-CML patients receiving imatinib therapy (White et al, 2007b,
2010). In some patients the negative impact of a low OA may be
partially overcome by escalating imatinib dosage where tolerated
(Hughes et al, 2008; White and Hughes, 2012). However, clinical
experience has demonstrated that increasing imatinib dose is
related to higher rates of adverse events and may lead to dosage
interruptions or cessation (Cortes et al, 2010).
Several commonly prescribed drugs have been identified as
substrates or inhibitors of OCT-1, thus, the contribution of OCT-1
to drug–drug interactions (DDI) has been reported recently in
several pharmacokinetic studies (Kindla et al, 2009; Fahrmayr
et al, 2010). Most of these studies used cell lines stably expressing
OCT-1, with 1-methyl-4-phenylpyridinium (MPPþ ) and metfor-
min as test compounds. In MDCKII-OCT-1 cells, OCT-1 mediated
MPPþ and metformin uptake were inhibited by oral anti-diabetic
drugs, rosiglitazone and repaglinide (Bachmakov et al, 2008).
Antiretroviral drugs for HIV treatment and cardiovascular drugs
have been found to inhibit OCT-1 mediated MPPþ uptake in
transformed HEK293 cells expressing OCT-1 and in primary
hepatocytes (Jung et al, 2008; Umehara et al, 2008). Although there
is accumulating evidence regarding OCT-1-mediated DDI, few
studies have investigated the effect of DDI on OCT-1 mediated
imatinib uptake. Minematsu and Giacomini (2011) reported the
selective and potent inhibitory effect of imatinib on 14C-metformin
uptake using HEK293 cells stably expressing OCT-1. However, the
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DDI involving imatinib and OCT-1 in CML cells has not been fully
assessed to date.
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of
structurally diverse drugs that effectively inhibit cyclooxygenases
(COX-1 and COX-2) (Ulrich et al, 2006). Non-steroidal anti-
inflammatory drugs are very commonly used for treatment of
arthritic conditions and different types and severities of inflam-
mation. There has been abundant evidence of DDI between
NSAIDs and other co-administrated drugs, which may prolong the
plasma elimination and lead to various side effects such as liver
damage (Bjorkman, 1998), kidney dysfunction (Perneger et al,
1994), and aggravation of cardiovascular diseases (Farooq et al,
2008). Recently, several studies suggested that the transporter
responsible for the renal uptake and secretion for NSAIDs is the
human organic anion transporter-1 (OAT-1) (Apiwattanakul et al,
1999; Nozaki et al, 2004; Honjo et al, 2011). At clinically relevant
concentrations, NSAIDs efficiently inhibit hOAT-1-mediated
transport of adefovir in a cell line stably expressing hOAT-1
(Mulato et al, 2000). Although it has been reported that NSAIDs
are not substrates of OCT transporters (Khamdang et al, 2002),
NSAIDs such as diclofenac, ibuprofen, indomethacin and sulindac
have been demonstrated to significantly inhibit OCT-1-mediated
TEA uptake at the concentration of 0.5mM in transfected S2 cells
expressing hOCT-1 (Khamdang et al, 2002). As about one-quarter
to one-half of CML patients on imatinib develop musculoskeletal
complaints (muscle cramps, myalgia, arthralgia), which may
need to be managed with NSAIDs (Deininger et al, 2003), it is of
particular relevance to investigate the effect on imatinib uptake of
NSAIDs. An understanding of the effects that these drugs may have
on imatinib influx in BCR-ABL-positive cells is of significant value
for clinical practice.
In this study we performed a systematic functional analysis of the
effects of 12 commonly used NSAIDs on imatinib uptake via OCT-1
in CML cell lines, and de novo CP-CML patients’ cells. As previous
studies have demonstrated that the influx of nilotinib and dasatinib
are not mediated by OCT-1 (White et al, 2006; Giannoudis et al,
2008; Hiwase et al, 2008), imatinib was selected as the only relevant
substrate for the OCT-1 transporter in the current study. Our data
demonstrates that NSAIDs result in varying effects on OA. Among
them two widely used NSAIDs, diclofenac and ibuprofen, resulted in
significant change in the OA, kinase inhibition and imatinib efficacy
in vitro at clinically achievable total plasma concentrations (10mM
for diclofenac and 130mM for ibuprofen) (Siu et al, 2000; Juhlin et al,
2004; Bramlage and Goldis, 2008). Thus, their concomitant use with




Human BCR-ABL-positive K562 and KU812 CML cell lines
were obtained from the American Type Culture Collection (ATCC,
Manassas, VI, USA). All cell lines were cultured in a 37 1C
humidified atmosphere of 5% CO2 in RPMI-1640 media (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10% foetal bovine
serum (JRH Biosciences, Lenexa, KS, USA), 2mM L-glutamine
(SAFC Biosciences, Lenexa, KS, USA) and 100Uml 1 penicillin
G/streptomycin (Sigma-Aldrich).
Patient samples
Blood was obtained from de novo CP-CML patients, before the
commencement of imatinib therapy. Normal blood was obtained
from healthy volunteers. All blood samples were collected with
informed consent in accordance with the Declaration of Helsinki.
Mononuclear cells (MNCs) were isolated from blood using
Lymphoprep (Axis Shield, Oslo, Norway) density gradient
centrifugation. Experiments were performed on fresh or frozen
cells. Use of clinical trial patients’ samples (TIDELI) was approved
by the Royal Adelaide Hospital Research Ethics Committee
(Novartis protocol No: CST15710106).
Drugs
Imatinib mesylate, together with labelled imatinib ([14C]-STI571)
were kindly provided by Novartis Pharmaceuticals (Basel,
Switzerland). Celecoxib and rofecoxib were purchased from
Toronto Research Chemicals (Ontario, CA, USA). Paracetamol
was kindly provided by Professor Andrew A Somogyi, the
University of Adelaide (Adelaide, Australia). Other NSAIDs were
purchased from Sigma-Aldrich and dissolved as per manufac-
turer’s instructions. For those drugs dissolved in DMSO or ethanol,
the final concentration of the solvents ranged from 0.14–0.25% (v/
v). The concentrations of NSAIDs used in this study were selected
according to the concentrations reported to be the maximum
plasma concentrations after therapeutic dosing. For those of which
the optimal concentrations were unknown, the concentrations
commonly chosen in high-throughput cell-based small-molecule
screens were used (Supplementary Table 1). The OCT-1 inhibitor
prazosin (Sigma-Aldrich) was dissolved in methanol and used at
100mM. The final concentration of methanol was 1% (v/v).
Radio-labelled drug uptake (IUR) assay and OA assay:
assessment of the effects of NSAIDs on OA modulation
As previously described (White et al, 2007b), the radio-labelled
intracellular uptake and retention (IUR) assay measures the
intracellular concentration of imatinib achieved and maintained
in cells over a 2-hour period. Non-steroidal anti-inflammatory
drugs and the potent inhibitor of OCT-1, prazosin were added to
the IUR assay simultaneously with radio-labelled imatinib. After
incubation, the cellular and aqueous phases were separated and
incorporation was determined using a Topcount Microplate Beta
Scintillation counter (Canberra Packard, Meriden, CO, USA)
following the addition of Microscint20 scintillation fluid (Perkin
Elmer, Boston, MA, USA). The OA was determined by calculating
the difference of the IUR with or without 100 mM prazosin.
IC50imatinibassay: assessment of the effects of NSAIDs
on tyrosine kinase inhibition
The IC50 assay was performed as previously described (White
et al, 2005), based on the in vitro reduction in the level of
phosphorylated Crkl (p-Crkl) as a result of exposure to increasing
concentrations of imatinib (ranged from 0 to 100mM). The
percentage of p-Crkl to non-p-Crkl at 0 mM imatinib was
standardised to 100%, and all other data points were normalised
to this value. The IC50 was defined as the concentration of
imatinib producing a 50% decrease in the level of p-Crkl compared
with untreated controls. The effects of NSAIDs were determined by
comparing the IC50 in the presence and absence of NSAIDs in cell
lines and primary patients’ material.
Trypan blue exclusion assay: assessment of the effects
of NSAIDs on the number of viable cells in the presence
of imatinib
After treatment with NSAIDs and various concentrations of
imatinib (indicated in the text) for 72 hours, cells were harvested
and viable cell numbers were assessed using the trypan blue
(Sigma-Aldrich) exclusion method. The number of viable cells was
then compared with a control treatment in the absence of NSAIDs.
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RQ-PCR assay: assessment of the effects of NSAIDs on
OCT-1 mRNA levels
The RQ-PCR for transporter mRNA expression was performed as
previously described (White et al, 2007b). The cells were
harvested after 2-hour incubation with NSAIDs. RNA was then
extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA).
The sequences for the primers were as follows: OCT-1 forward
50-CTGAGCTGTACCCCACATTCG-30, OCT-1 reverse 50-CCAACA
CCGCAAACAAAATGA-30.
Statistical analyses
All statistical analyses are indicated where applied and were
performed using Sigma Stat Software 3.0 (Systat Software Asia
Pacific Ltd, Richmond, CA, USA). The unpaired t-test was used to
define differences between blank and NSAIDs-treated group, and
correlation was performed using the Pearson Product Moment.
Data are presented as mean±s.e.m. for at least three biological
replicates. Differences were considered to be statistically signifi-
cant when the P-value was less than 0.05.
RESULTS
Effects of NSAIDs on OA and IC50imatinib of
BCR-ABL-positive cell lines
Diverse effects on OA were observed in BCR-ABL positive cell lines
(K562 and KU812) in the presence and absence of NSAIDs.
Although the majority of NSAIDs selected (9 of 12) failed to induce
any significant change in OA (Figure 1A), a significant increase in
OA was observed in K562 cells treated with either 10 mM diclofenac
(27%, n¼ 4, P¼ 0.007) or 16 mM fenbufen (33%, n¼ 9, P¼ 0.006),
Similarly, a 22% increase was observed in OA when KU812 cells
were treated with 10 mM diclofenac (n¼ 6, P¼ 0.003, Figure 1B).
Although not significant, incubation with fenbufen resulted in a
21% increase in OA in KU812 cells (n¼ 5, P¼ 0.328). Surprisingly,
and in contrast, the OA was reduced in the presence of ibuprofen
(48% of vehicle control in K562, n¼ 4, Po0.001, Figure 1A; 59%
of vehicle control in KU812, n¼ 6, Po0.001, Figure 1B). As
diclofenac and ibuprofen demonstrated the most significant effect
on OA, and as both are commonly used in clinical practice, these
drugs were selected for further experimentation.
Effects of diclofenac and ibuprofen on IC50imatinib
of BCR-ABL-positive cell lines
To assess whether the observed divergent alterations in OA
translate into changes in tyrosine kinase inhibition, the IC50imatinib
was examined in K562 and KU812 cells with or without diclofenac
or ibuprofen. A significant decrease in the IC50imatinib was
observed in K562 cells when treated with diclofenac (5.7±0.8 to
3.7±0.7 mM, P¼ 0.013, n¼ 3, Figure 2A). In addition, a similar
decrease was observed in the KU812 IC50imatinib in the presence of
diclofenac (3.5±0.6 to 2.2±0.4 mM, P¼ 0.007, n¼ 3, Figure 2B).
In contrast, ibuprofen significantly elevated the IC50imatinib in
K562 and KU812 cells (5.7±0.8 to 8.1±0.5mM and 3.5±0.6 to
6.6±0.8 mM, respectively; Po0.001, n¼ 3).
Effects of diclofenac and ibuprofen on viable cell counts
when co-administrated with imatinib and OCT-1 mRNA
levels in BCR-ABL-positive cells
To address whether the changes in imatinib intracellular
concentration and IC50imatinib mediated by diclofenac or ibuprofen
translate to changes in viable cell number, the trypan blue cell
exclusion assay was performed with K562 and KU812 cells in the
presence or absence of diclofenac and ibuprofen. After 72 hours
incubation with varying doses of imatinib as shown in Figure 3,
KU812 cells are more sensitive to the effects of imatinib than K562
cells. Thus, different doses of imatinib were used in K562 and
KU812 cells. At relatively low doses of imatinib (0.25 mM for K562
cells; 0.05mM for KU812 cells), diclofenac resulted in a significantly
lower number of viable cells after 72 hours compared with imatinib
alone (7.82±0.56 105ml 1 vs 10.95±1.01 105ml 1 in K562
cells: P¼ 0.021, n¼ 3; 5.40±0.34 105ml 1 vs 8.40±0.74
105ml 1 in KU812 cells: P¼ 0.019, n¼ 3, Figures 3A and B),
which is consistent with the observed decrease in IC50imatinib.
Interestingly, this effect is not due to diclofenac-induced cell death
as there was no significant change observed in cell viability in the
presence or absence of diclofenac alone.
In contrast, when K562 or KU812 cells were co-incubated
with imatinib and ibuprofen there was a significant increase in
viable cell number compared with cells treated with imatinib alone
(8.16±1.01 105ml 1 vs 4.88±0.96 105ml 1 in K562 cells



























































































Figure 1 Non-steroidal anti-inflammatory drugs induce divergent effects
on OCT-1 activity in BCR-ABL-positive cells. NSAIDs and the potent
inhibitor of OCT-1, prazosin, were added to the OCT-1 activity assay
simultaneously with 14C-imatinib. After 2-hour incubation, the OA was
determined by calculating the difference of the intracellular uptake and
retention with or without prazosin. Results (mean±s.e.m.) are expressed
as percentage of own solvent control, which was set at a value of 100%, for
at least three biological replicates. *Po0.05 vs control; **Po0.001 vs
control. (A) OCT-1 activity in the presence of 12 NSAIDs in K562 cells.
(B) OCT-1 activity in the presence of 10 mM diclofenac, 16 mM fenbufen and
145 mM ibuprofen in KU812 cells.
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4.97±0.47 105ml 1 in KU812 cells at 0.1 mM of imatinib,
P¼ 0.002, n¼ 3, Figures 3A and B).
To determine whether the level of OCT-1 mRNA was affected by
the presence of NSAIDs OCT1 transcript levels were analysed
following a 2-hour incubation in the presence and absence of
NSAIDs in both K562 and KU812 cells. There was no significant
change in the level of OCT-1 mRNA with diclofenac or ibuprofen
over the 2-hour period (data not shown), suggesting that these
NSAIDs function via a post-transcriptional mechanism.
Effects of diclofenac and ibuprofen on the OA of
primary cells
Our previous TIDEL study in newly diagnosed CML patients
receiving imatinib at 600 mg per day has described the link
between OA and achievement of optimal or sub-optimal molecular
response. The percentage of patients with high OA achieving major
molecular response (MMR) by 24 months was significantly greater
than that of patients with low OA (85% vs 45%, P¼ 0.004) (White
et al, 2007b). Dividing the OA groups further into quartiles,
patients with OA in the lowest quartile (Q1, OAo4 ng per 200 000
cells) have a significantly poorer response to imatinib treatment
than those in higher quartiles (White et al, 2010). To examine the
effect of both drugs on OA in primary CML samples, OA of MNCs
isolated from TIDEL patients were assessed in the presence or
absence of 10 mM diclofenac or 145 mM ibuprofen.
We then compared the effect of diclofenac on MNCs from
patients with OA in Q1 (OA less than 4 ng per 200 000 cells) with
the effect observed in patients with OA greater than 4 ng per
200 000 cells. After treatment with diclofenac, the OA was increased
in 93% of the Q1 patients’ samples tested. The median OA in Q1
patients rose from 1.39 to 4.17 ng per 200 000 cells (n¼ 29,
Po0.001). Notably, as the result of this increase, 15 of 29 cases
(51.7%) moved from Q1 to a higher OA quartile group (Figure 4A).
However, for patients with higher basal OA value, treatment with
diclofenac did not lead to a significant increase in OA (median OA
in the absence or presence of diclofenac: 5.49 ng/200,000cells vs
5.92 ng per 200 000cells, n¼ 21, P¼ 0.714, Figure 4B). The different
effect of diclofenac between quartiles indicated that the increase in
OA mediated by diclofenac was largely confined to patients with
low OA rather than in patients with higher OA.
In MNCs treated with ibuprofen, a consistent inhibitory effect
(41% reduction in OA) was observed in all 12 cases tested
(Figure 4C). The average OA in these 12 samples (7.53±0.82 ng per
0
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Ibuprofen (IC50=6.6±0.8 M)**
Figure 2 The IC50imatinib results in the presence or absence of 10mM
diclofenac or 145 mM ibuprofen. The in vitro reduction in the level of p-Crkl
by imatinib was detected using the IC50imatinib assay. Cells were incubated
with 10mM diclofenac or 145 mM ibuprofen and increasing concentrations of
imatinib for 2 hours. The percentage of p-Crkl to non-p-Crkl at 0 mM
imatinib was standardised to 100%, and all other data points were
normalised about this value. The IC50 was defined as the concentration of
imatinib producing a 50% decrease in the level of p-Crkl compared with
untreated controls. Error bars represent mean±s.e.m. for three biological
replicates. *Po0.05 vs control; **Po0.001 vs control. The cumulative
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Figure 3 The effects of diclofenac and ibuprofen on the number of
viable cells after 72 hours co-incubation with imatinib. The number of viable
cells was determined using the trypan blue exclusion method after
treatment with NSAIDs and imatinib for 72 hours. 10mM diclofenac co-
administered with imatinib induced a significantly lower viable cell number
compared with imatinib alone. Conversely, the viable cell numbers were
significantly increased by 145 mM ibuprofen with imatinib, especially at
relatively higher concentration of imatinib. The results (mean±s.e.m) are
expressed as the viable cell number determined by trypan blue exclusion
assay of three biological replicates. *Po 0.05 versus control. (A) in K562
cells (n¼ 3) (B) in KU812 cells (n¼ 3).
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200 000 cells, range 3.53–14.52) was significantly reduced
(4.30±0.52 ng per 200 000 cells, range 1.53–7.85, Po0.001) after
the treatment with ibuprofen.
In addition, we have examined the effect of diclofenac (n¼ 10)
or ibuprofen (n¼ 6) on MNCs collected from normal individuals.
Diclofenac did not result in a significant change in OA (data not
shown), however, a 50% decrease in OA was observed following
ibuprofen treatment (OA before treatment: 3.70±0.45 ng per
200 000 cells, range 2.21–4.89; OA post treatment: 1.83±0.26 ng
per 200 000 cells, range 1.41–2.82, Po0.001, Figure 4D).
The impact of diclofenac on the IC50imatinib in
primary cells
As diclofenac resulted in a significant increase in OA in MNCs of
CP-CML patients, its impact on in vitro kinase inhibition was
determined in 9 de novo CP-CML patients. Patients were chosen
based on the availability of sufficient fresh blood cells for
this analysis, not on the basis of OA. The median IC50imatinib of
this group was 1.2 mM (range 0.5–1.7 mM). A significant reduction
was observed when diclofenac was added (median IC50imatinib
reduced to 0.75 mM, range 0.25–1.15 mM, P¼ 0.018, Figure 5).
DISCUSSION
The interaction between NSAIDs and OCT-1 remains unknown but
has significant potential to impact response to imatinib. Here we
investigate the potential involvement of NSAIDs in targeted cancer
therapy where transport of the anti-leukaemic drug into leukaemic
cells has a major role in patient response. Twelve NSAIDs were
selected in this study; including the commonly used diclofenac,
ibuprofen, naproxen, and celecoxib. Their effects on OCT-1 were
first validated in assays of imatinib uptake (IUR). Two NSAIDs
with the most significant effects on OA, diclofenac and ibuprofen,
were then chosen for IC50imatinib and cell proliferation assays using
CML cell lines.
As OCT-1 is the major active influx transporter for imatinib, OA
is a strong predictor of response to imatinib treatment in de novo
CML patients (White et al, 2005, 2007a). Here our data
demonstrated that OA was increased in BCR-ABL-positive cell
lines (K562 and KU812) by diclofenac. Importantly, this increase
in OA translated to a significant increase in BCR-ABL kinase
inhibition as demonstrated by a reduction in the IC50imatinib in
both cell lines. This finding also highlights, in line with our
previous studies (White et al, 2007b), the correlation between
OA and IC50imatinib. In addition, trypan blue exclusion assays
provided further evidence that by increasing functional OA and
tyrosine kinase inhibition, diclofenac in combination with
imatinib results in a significant reduction in viable cell numbers.
Interestingly, the effect of diclofenac was also observed in CML
patients’ samples. In 93% of MNCs samples from CML patients
with basal OA less than 4 ng per 200 000 cells (Q1), we
demonstrated a significant increase in OA in the presence of
diclofenac at clinically relevant concentrations. Importantly, 51.7%
of Q1 cases tested increased from Q1 to higher quartiles. From a
clinical perspective, this increase is of greater significance for the
Q1 patients who have a particularly poor outcome on standard
imatinib therapy. On the basis of the TIDEL data this may
significantly increase the probability of these patients achieving a
MMR, and significantly reduce the risk of suboptimal response or
imatinib failure (White et al, 2010). However, diclofenac did not
significantly increase OA in cells from patients with higher OA.
This differential effect of diclofenac in patients with higher OA
suggested that this population may not be targeted as well as Q1 by
diclofenac intervention.
When applied to MNCs from healthy donors, diclofenac did not
mediate the same effect as seen in CML patients, implicating a role
for BCR-ABL or disease-related processes in this interaction. These
findings raise the possibility that combination therapy with
imatinib plus diclofenac may be more effective than imatinib
alone, although not adding greatly to the toxicity of the therapy.
Importantly from a clinical perspective, this may translate to an
increase in the probability of patients with low OA achieving a
MMR, and a significantly reduced risk of suboptimal response or
imatinib failure. In addition, this strategy may also benefit patients
with low OA by allowing for a lower/standard dosage of imatinib
(400mg per day) without adding greatly to the toxicity commonly
observed when higher doses of imatinib are used (600 or 800mg
per day). However, extrapolations of in vitro effects to in vivo
effects and clinical response will require careful validation.
Another interesting finding in this study is that NSAIDs can


































































n =21, P =0.714
Figure 4 The effects of diclofenac or ibuprofen on OA in primary
MNCs. OCT-1 activity assays were performed with fresh or frozen MNCs
isolated from the blood of newly diagnosed patients with CML. Box-plots
display the median value, the minimum and maximum value of OA.
(A) 10mM diclofenac increased OA in patients with basal OA less than 4 ng
per 200 000 cells (n¼ 29). (B) No significant increase was observed in
patients with basal OA greater than 4 ng per 200 000 cells (n¼ 21).
(C) Decreased OA in MNCs from de-novo CP-CML patients were
observed after treatment of 145 mM ibuprofen (n¼ 12). (D) Ibuprofen
















Figure 5 The impact of diclofenac on the IC50imatinib in primary MNCs
from de-novo CP-CML patients. Mononuclear cells samples from 9 de-novo
CP-CML patients were incubated with 10mM diclofenac and increasing
concentrations of imatinib for 2 hours. The percentage of p-Crkl to non-p-
Crkl at 0mM imatinib was standardised to 100%. All other data points were
normalised about this value. The IC50 was defined as the concentration
of imatinib achieving a 50% decrease of p-Crkl compared with no imatinib
controls. When there were sufficient MNCs, analysis was performed in
duplicate. Box-plots display the median value, the minimum and maximum
value of OA.
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NSAIDs have antipyretic, analgesic, and anti-inflammatory proper-
ties, there are several important differences in their activities that
are mostly due to their affinity towards COX enzyme isoforms:
COX-1 and COX-2. In CML, it was reported that expression of
COX-2 was significantly higher in CML than in healthy volunteers
and the increasing levels of COX-2 were significantly associated
with shorter survival (Giles et al, 2002). Therefore several studies
have been conducted to investigate the role of COX-2 in imatinib
resistance and the use of COX-2 inhibitors as an alternative
therapy. It has been reported that celecoxib, a COX-2 inhibitor,
reduced cell growth with arrest of the cell cycle at G0/G1 phase and
induction of apoptosis by inhibiting NF-kB activation in K562 cells
(Subhashini et al, 2005). In imatinib-resistant K562 (IR-K562)
cells, over-expression of COX-2 and MDR-1 were observed and in
addition, celecoxib could induce cell apoptosis by inhibiting COX-
2 and MDR-1 (Arunasree et al, 2008), probably through the PGE2-
cAMP-PKC-mediated pathway (Kalle et al, 2010). However, we did
not observe any universal effect among COX-2 inhibitors in this
study. Although sharing similar COX-2 selectivity with diclofenac
(Rich, 2001), celecoxib, as well as another more potent selective
COX-2 inhibitor, rofecoxib, had no significant impact on imatinib
uptake via OCT-1 in K562 or KU812 cells. This finding suggests
that COX-2 inhibitors are unlikely to be the critical mediator of the
interaction between OCT-1 and diclofenac observed in this study.
Unexpectedly, although diclofenac increased OA significantly,
ibuprofen significantly decreased the OA in both K562 and KU812
cells. This effect on OA translated into an increase in IC50imatinib
and cell growth in the presence of imatinib. Given the common
administration and over-the-counter access of ibuprofen, this
finding is likely to be of significant clinical relevance. Unlike
diclofenac, the effect of ibuprofen is also observed in normal cells
to the same extent as leukaemic cells, suggesting that the
mechanisms of these two interactions are different.
The various effects of NSAIDs on OCT-1-mediated DDI
is in contrast with a previous study reporting that diclofenac,
ibuprofen, indomethacin and sulindac could all significantly
inhibit OCT1-mediated TEA uptake (Khamdang et al, 2002).
However, it should be noted that the concentration of NSAIDs
used in that study (0.5mM) was much higher than the concentra-
tions used in our study. Given that the mean maximum plasma
concentration (Cmax) of diclofenac after a single dose of 50 mg in
healthy volunteers is 5 mM (Siu et al, 2000; Juhlin et al, 2004), the
dose used in this study is more relevant to the clinical setting.
Similarly, the concentration of ibuprofen used here (145 mM, equal
to 30 mgml 1) is determined according to the clinically achievable
level (Cmax¼ 37 mgml 1, after 400mg single administration in
healthy volunteers) (Bramlage and Goldis, 2008). Although
this concentration is also lower than 0.5 mM, it is still much higher
(up to 20-fold) than other NSAIDs selected in the current work. As
it has been shown that NSAIDs are not substrates of OCT
transporters (Khamdang et al, 2002), it is unlikely that ibuprofen
inhibits imatinib uptake by competing for OCT-1. Molecular
structural analysis is necessary to further understand the interac-
tion between ibuprofen and imatinib at the binding site of OCT-1.
We did not observe changes in OCT-1 mRNA that could explain
the differences in imatinib uptake and intracellular level. Thus, the
major cause of increased OA and kinase inhibition in these short-
term assays may be from the effects of these drugs on the
post-transcriptional regulation of OCT-1. So far a number of post-
transcriptional mechanisms for OCT-1 modulation have been
reported, including protein kinase A phosphorylation sites which
can affect transporter regulation and substrate specificity
(Ciarimboli et al, 2004; Ciarimboli et al, 2005; Holle et al, 2011).
Other regulatory pathways identified in transfected Chinese
hamster ovary cells include p56lck, calmodulin and the calmodu-
lin-dependent protein kinase II (Ciarimboli et al, 2004). However,
the mechanisms underlining OCT-1 regulation in leukaemic cells
remains unknown. Further studies are required to establish
whether these drugs affect these pathways or impact on OCT-1
transcript or protein levels over longer time periods, or with
constant in vivo exposure as would occur clinically. Better
understanding of OCT-1 regulation and imatinib influx may lead
to additional approaches and drug candidates to enhance imatinib
efficacy in CML.
In conclusion, this study provides evidence for interactions
between selected NSAIDs and imatinib that directly impact on
leukaemic cell response, suggesting that these drugs have the
potential to impact significantly on CML patient outcome. The
effect of NSAIDs on OA was highly selective suggesting that the
mechanism is not related to direct COX inhibition and further
studies are required to establish the nature of the interaction in
leukaemic cells. Although drugs such as diclofenac may have a
positive influence on imatinib efficacy, this is in contrast to the
effect seen with ibuprofen suggesting caution is required when
administrating NSAIDs to CML patients on imatinib treatment.
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